CClinicalTrials.gg
CompletedNCT01184677Updated Aug 27, 2012

ProSeal Laryngeal Mask Airway (LMA) Size 3 vs 4 in Non-paralyzed Female Patients

An interventional study of insertion of the ProSeal LMA (PLMA) and insertion of the PLMA in Oropharyngeal Injury, sponsored by Seoul National University Bundang Hospital. Completed at 1 site in Korea, Republic of. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2012-08-27.

Sponsored by Seoul National University Bundang Hospital · Not applicable and Interventional

Phase
Not applicable
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
Female
01

Study summary

The investigators hypothesize that ProSeal laryngeal mask airway (PLMA) of smaller size would reduce the incidence of mucosal injury.

Read the detailed description

The ProSealTM laryngeal mask airway (PLMA; Laryngeal Mask Co. Limited, Mahe, Seychelles) is a laryngeal mask device with an added dorsal cuff to improve the seal and a drainage tube to prevent aspiration and gastric insufflations(Brain, Verghese et al. 2000).Despite its utility, there are complications associated with PLMA insertion such as sore throat and mucosal injury including oropharyngeal blood.

The purpose of this randomized controlled study is to determine if size 3 PLMA would induce less mucosal damage indicated by blood on the cuff than size 4 in non-paralyzed female patients. The secondary objective of this study is to compare insertion time, number of attempts, oropharyngeal leak pressure, hemodynamic variables, and incidence of complications with size 3 and 4 PLMA.

02

Conditions studied

  • Oropharyngeal Injury
03

In context

Lead sponsor

Seoul National University Bundang Hospital is the lead sponsor of 368 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • female
  • aged 18-80 yr
  • American Society of Anesthesiologists physical status Ⅰ-Ⅱ
  • scheduled to undergo short outpatient gynecological procedures using ProSealTM LMA (PLMA) for anesthesia

Exclusion criteria

Exclusion Criteria:

  • a known or predicted difficult airway
  • recent sore throat
  • mouth opening less than 2.5 cm
  • body mass index > 35 kg/m2
  • at risk of aspiration.
05

Study design

Phase
Not applicable
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
154 participants (actual)

Study arms

  • Placebo comparator
    Group size 4

    Device: insertion of the PLMA

  • Experimental
    Group size 3

    ProSeal LMA size 3 is inserted to the patients of Group size 3.

    Device: insertion of the ProSeal LMA (PLMA)

Interventions

  • Deviceinsertion of the ProSeal LMA (PLMA)

    ProSeal LMA size 3 is inserted to the patients of Group size 3.

    Also known as: insertion, ProSeal LMA size 3

  • Deviceinsertion of the PLMA

    ProSeal LMA size 4 is inserted to the patients of Group size 4.

    Also known as: insertion, ProSeal LMA size 4

06

What researchers measure

Primary outcomes

  1. blood on the ProSeal LMA

    The incidence of blood on the proseal LMA upon removal of the device is assessed in each group.

    Time frame: from the start of ProSeal LMA insertion until the end of the anesthesia (around 30min , mostly less than 60min)

Secondary outcomes

  1. hemodynamic variables

    mean arterial pressure and heart rate before and after the Proseal LMA insertion are measured.

    Time frame: from induction of anesthesia until immediately after the Proseal LMA insertion

  2. insertion time

    Time frame: from grasping the Proseal LMA until an effective airway is established

  3. seal pressure

    oropharyngeal leak pressure

    Time frame: after successful insertion of Proseal LMA

  4. other intraoperative complications

    airway leak, failed ventilation, regurgitation/aspiration, laryngospasm, cough/gag/retching/hiccup.

    Time frame: from successful insertion of PLMA until the end of the anesthesia

  5. postoperative complications

    sore throat and hoarseness

    Time frame: from removal of Proseal LMA until discharge from recovery room

07

Study locations

1 site
  • Seoul National University Bundang Hospital
    Seongnam, Gyeonggi-do 463-707, Korea, Republic of
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01184677
Lead sponsor
Seoul National University Bundang Hospital
Responsible party
Kim Mihyun (professor, Seoul National University Bundang Hospital) — Principal investigator
First posted
Aug 19, 2010
Start date
Aug 2010
Primary completion
Dec 2011
Completion
Feb 2012
Last update
Aug 27, 2012

Study contacts

Mihyun Kim, professor
principal investigator · Seoul National University Bundang Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion